11/06/2026 Nipocalimab demonstrated a durable hemoglobin response and rapid onset of effect in a Phase 2/3 study in wAIHA Climb Bio announced initial Phase 1b data for budoprutug in ITP at EHA Congress 2026 Nipocalimab demonstrated a durable hemoglobin response and rapid onset of effect in a Phase 2/3 study in wAIHA (Ref) Johnson & Johnson presented results from the Phase 2/3, ENERGY/ NCT04119050 study which showing that IMAAVY® (nipocalimab-aahu; FcRn) produced a statistical

22/04/2026 Roche announced Phase 3 data for fenebrutinib in RMS Johnson & Johnson announced Phase 3 data for nipocalimab in gMG Sanofi's Tzield approved in the US to delay the onset of stage 3 T1D in young children Roche announced Phase 3 data for fenebrutinib in RMS (Ref) Roche announced new positive data from the Phase 3 FENhance 1 and 2 studies, Which investigated fenebrutinib (BTK inhibitor) for the treatment of patients with Relapsing Multiple Sclerosis (RMS). FENhance 1

24/02/2026 Abcuro announced topline results from its Phase 2/3 study of ulviprubart in patients with inclusion body myositis J&J submitted sBLA to the US FDA for approval of IMAAVY® for warm autoimmune hemolytic anemia Abcuro announced topline results from its Phase 2/3 study of ulviprubart in patients with inclusion body myositis ( Ref ) Abcuro announced topline results from its Phase 2/3 MUSCLE/ NCT05721573 study, which evaluated ulviprubart (ABC008; anti-KLRG1) for the tre